Elisabet de los Pinos, Ph.D., is a distinguished leader in the biotechnology industry, currently serving as the President, Chief Executive Officer, and Director at AURA BIOSCIENCES INC. Dr. de los Pinos has been instrumental in steering the company towards its mission of developing innovative therapies for cancer treatment. With a Ph.D. in Molecular Biology from the University of Salamanca, Spain, and an MBA from the Sloan School of Management at MIT, she brings a unique blend of scientific and business acumen to her role. Her career spans over two decades, during which she has held various leadership positions in both large pharmaceutical companies and emerging biotech firms. Before joining AURA BIOSCIENCES INC, Dr. de los Pinos worked at companies such as Pfizer and Millennium Pharmaceuticals, where she gained extensive experience in drug development and commercialization. Her strategic vision and leadership skills have been pivotal in advancing AURA's lead candidate, AU-011, through clinical trials. AU-011 is a novel therapy aimed at treating ocular cancers, and under her guidance, the company has made significant progress in bringing this treatment closer to market. Dr. de los Pinos is also recognized for her contributions to the scientific community, having authored numerous publications and patents in the field of molecular biology and cancer research. As President and CEO of AURA BIOSCIENCES INC, Dr. de los Pinos is responsible for overseeing the company's overall strategy, operations, and growth. Her leadership has been crucial in securing partnerships and funding to support the company's research and development efforts. Under her direction, AURA has expanded its pipeline and strengthened its position in the competitive biotech landscape. Dr. de los Pinos is committed to improving patient outcomes and is driven by a passion for translating scientific discoveries into effective therapies. Her dedication to innovation and excellence continues to inspire her team and the broader scientific community.